Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
SVRA · Why this verdict
Why Savara (SVRA) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.9/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Savara is a pre-revenue biotechnology company in a golden cross breakout with 78% analyst price target upside, but quality scores only 1.6 out of 10 with fully negative free cash flow and a put/call ratio of 28.33 — the highest in this group — signaling extreme options market bearishness despite the bullish technical setup.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
A put/call ratio of 28.33 means 28 times as many put options as calls have been purchased, which is an extreme reading that suggests institutional investors are heavily hedging downside risk or making directional bearish bets against this stock, far exceeding any normal hedging pattern. Options | The put/call ratio falls below 10.0 within 12 months as hedging demand normalizes following a clinical or regulatory catalyst that resolves binary uncertainty. | →Stable |
| CounterIn a small, thinly traded biotech with limited options open interest, a single institutional hedge position can produce an extreme put/call ratio that does not reflect broad market consensus; the ratio may be statistically meaningless at low volume. | ||
The stock is in a golden cross with RSI at 57, MACD bullish, and trading above all moving averages, indicating technical confirmation of upward momentum that contrasts sharply with the quality concerns and extreme put/call ratio. Momentum breakdown | Price remains above the 200-day moving average and RSI stays between 50 and 70 for at least 6 months, confirming the breakout is sustained rather than a brief technical spike. | →Stable |
| CounterGolden crosses in pre-revenue biotech companies frequently reverse when clinical trial results disappoint; technical signals in fundamentally speculative companies have limited predictive value compared to data-driven catalysts. | ||
The quality score of 1.6 out of 10 is among the lowest possible ratings, with fully negative free cash flow, no revenues, no operating income, no net income, and no competitive moat established, meaning the entire value proposition rests on future clinical success. Quality breakdown | The company initiates at least 1 revenue-generating activity or partnership within 12 months, demonstrating that the pipeline is progressing toward commercial potential. | →Stable |
| CounterPre-revenue biotechs are specifically valued on pipeline probability-weighted outcomes, not current financial quality; a quality score of 1.6 in this context is expected and does not indicate the company is poorly managed. | ||
Analysts project 78.6% upside from the current $5.33 to approximately $9.52, yet the company has missed earnings estimates in 3 of the last 4 quarters with an average negative surprise of 7.0%, raising the question of whether the clinical timeline driving analyst targets is realistic. Earnings | The stock price rises above $7.50, more than 40% above the current $5.33, within 12 months as clinical progress narrows the gap to analyst targets. | →Stable |
| CounterEarnings misses in a pre-revenue biotech typically reflect burn rate acceleration rather than a business deterioration; if the cash is being deployed effectively into clinical development, the miss pattern is not a negative signal. | ||
A put/call ratio of 28.33 means 28 times as many put options as calls have been purchased, which is an extreme reading that suggests institutional investors are heavily hedging downside risk or making directional bearish bets against this stock, far exceeding any normal hedging pattern.
→StableOptions
- Expectation
- The put/call ratio falls below 10.0 within 12 months as hedging demand normalizes following a clinical or regulatory catalyst that resolves binary uncertainty.
CounterIn a small, thinly traded biotech with limited options open interest, a single institutional hedge position can produce an extreme put/call ratio that does not reflect broad market consensus; the ratio may be statistically meaningless at low volume.
The stock is in a golden cross with RSI at 57, MACD bullish, and trading above all moving averages, indicating technical confirmation of upward momentum that contrasts sharply with the quality concerns and extreme put/call ratio.
→StableMomentum breakdown
- Expectation
- Price remains above the 200-day moving average and RSI stays between 50 and 70 for at least 6 months, confirming the breakout is sustained rather than a brief technical spike.
CounterGolden crosses in pre-revenue biotech companies frequently reverse when clinical trial results disappoint; technical signals in fundamentally speculative companies have limited predictive value compared to data-driven catalysts.
The quality score of 1.6 out of 10 is among the lowest possible ratings, with fully negative free cash flow, no revenues, no operating income, no net income, and no competitive moat established, meaning the entire value proposition rests on future clinical success.
→StableQuality breakdown
- Expectation
- The company initiates at least 1 revenue-generating activity or partnership within 12 months, demonstrating that the pipeline is progressing toward commercial potential.
CounterPre-revenue biotechs are specifically valued on pipeline probability-weighted outcomes, not current financial quality; a quality score of 1.6 in this context is expected and does not indicate the company is poorly managed.
Analysts project 78.6% upside from the current $5.33 to approximately $9.52, yet the company has missed earnings estimates in 3 of the last 4 quarters with an average negative surprise of 7.0%, raising the question of whether the clinical timeline driving analyst targets is realistic.
→StableEarnings
- Expectation
- The stock price rises above $7.50, more than 40% above the current $5.33, within 12 months as clinical progress narrows the gap to analyst targets.
CounterEarnings misses in a pre-revenue biotech typically reflect burn rate acceleration rather than a business deterioration; if the cash is being deployed effectively into clinical development, the miss pattern is not a negative signal.
Per-dimension breakdown
Quality
1.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.4 |
| MACD | 8.2 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 0.0 |
- ▸Overbought (RSI 72)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.8/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.9 |
| Price target | 9.9 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (8.0) — signal dampened
- ▸Analyst upside: 84%
Insider
4.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| holder change | 5.0 |
- ▸Notable insider selling — $2,241,432 (0.188% of mkt cap)
Peer rank
2.6/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 0.3 |
| growth rank | 5.0 |
Technical
2.4/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 0.2 |
| 52w position | 7.0 |
Risk (lower is worse)
4.5/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.8 |
| days to cover | 0.0 |
| volatility | 1.6 |
| put call | 10.0 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| beta | 10.0 |
| debt equity | 9.3 |
- ▸High short interest justified: 17%
- ▸High IV: 328%
- ▸Above max pain $1
Catalyst
2.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
- ▸Earnings concerns: 1B/3M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (8)
- MOMENTUM:6.3>=5.5
- ASYMMETRY:4.0>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:49d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (0)
none
Reward-to-Risk
3.99
Upside
+59.8%
Downside
15.0%
Sizing output
AVOID
SetupUNKNOWN — No clear chart pattern; technical signals are mixed
EdgeNO_EDGE — No clear edge identified
SuitabilityAGGRESSIVE — MCap $1.2B<$5B
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 9.0 could not lift the engine output above the verdict floor.
The strongest dimensions are Value at 9.0, Sentiment at 7.8, and Momentum at 6.3; the weakest are Quality at 1.6, Technical at 2.4, and Catalyst at 2.5. The V9 engine cleared all gates, producing an asymmetric reward-to-risk of 3.99 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1A put/call ratio of 28.33 means 28 times as many put options as calls have been purchased, which is an extreme reading that suggests institutional investors are heavily hedging downside risk or making directional bearish bets against this stock, far exceeding any normal hedging pattern.
Trip ifPut/call ratio rises above 40.0, exceeding the already extreme 28.33 level, indicating further acceleration of bearish options positioning.
- P2The stock is in a golden cross with RSI at 57, MACD bullish, and trading above all moving averages, indicating technical confirmation of upward momentum that contrasts sharply with the quality concerns and extreme put/call ratio.
Trip ifPrice drops below $4.00, more than 25% below the current $5.33, breaking the golden cross setup and signaling the breakout has failed.
- P3The quality score of 1.6 out of 10 is among the lowest possible ratings, with fully negative free cash flow, no revenues, no operating income, no net income, and no competitive moat established, meaning the entire value proposition rests on future clinical success.
Trip ifCash and equivalents fall below $30 million, suggesting less than 12 months of runway remain at the current burn rate.
- P4Analysts project 78.6% upside from the current $5.33 to approximately $9.52, yet the company has missed earnings estimates in 3 of the last 4 quarters with an average negative surprise of 7.0%, raising the question of whether the clinical timeline driving analyst targets is realistic.
Trip ifEPS surprise falls below negative 20% in at least 3 of the next 4 quarters, indicating the clinical investment is accelerating the cash burn faster than analysts model.